Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Trial Profile

Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2012

At a glance

  • Drugs Chlormethine; Givinostat
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Oct 2012 Planned number of patients changed from 21 to 23.
    • 08 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top